Diabetes Care Volume 39, Supplement 1, January 2016 S109

Index

A1C body mass index (BMI), S17 smoking in, S29, S89 age in diagnosis, S14 bromocriptine, S55 statins in, S89 CGM effects on, S39, S40, S101 thyroid disease in, S88 in children, S18, S41 calcium channel blockers, S74 type 1 diabetes in, S86–S90 in children, adolescents, S87 canagliflozin, S53, S54, S56, S58 type 2 diabetes in, S90–S91 CVD outcomes and, S42–S43 cancer, S31 vaccination schedule, S29 diagnostic criteria, S13–S14 capsaicin, S77 chlorthalidone, S63 epidemiology, S7 carbamazepine, S77 Chronic Care Model, S7, S23 goals, S41 carbohydrates, S27, S37 chronic kidney disease, S27, S72–S74 hyperglycemia and, S9–S10 cardiac autonomic neuropathy, S77 Chronic Kidney Disease Epidemiology limitations, S41 cardiac testing, S67 Collaboration (CKD-EPI) equation, S73 mean glucose levels for specified A1C level, cardiovascular disease classification, S13 S41 antiplatelet agents, S4–S5, S66–S67, S75 clinical evaluation, S23, S24 microvascular complications, S42 in children, adolescents, S88–S89 clopidogrel, S66 older adults, S83 heart failure, S68 clozapine, S49 pregnancy levels, S95 hypertension/blood pressure cognitive dysfunction, S9–S10, S26, S31–S32, race/ethnicity differences, S14, S41 control, S60–S63, S81, S88–S89 S44, S82 recommendations, S40, S41 insulin regimens, S43 cognitive function, statin use and, S66 testing, S40–S41 LDL cholesterol, S64, S65, S68 colesevelam, S55 acarbose, S55 lifestyle modification, S7, S36–S37, S47, complications access to health care, S8–S9 S48, S62–S64, S68 A1C, microvascular, S42 ACCORD trial, S10, S31–S32, S42–S44, S61, S62 lipid management, S63–S66 epidemiology, S8 ACE inhibitors, S61–S63, S68, S72–S74, S89, outcomes, S42–S43, S73 prevention of, S7, S27 S97 overview, S4, S60 risk factors, S14, S29 ADAG study, S41, S44 pharmacological interventions, S62–S63 consensus reports, S1 adherence, S8 prevention, S26, S27, S37 continuous glucose monitoring (CGM), S39, S40, ADVANCE trial, S42–S44, S61 risk calculator tool, S64 S101 advocacy, S6, S105–S106 as risk factor, S16, S60 Contrave (naltrexone/bupropion), S50 African Americans, S14, S15, S27 risk factors for, S15, S17, S29, S31, S60, coronary artery calcium screening, S67–S68 AIM-HIGH trial, S65–S66 S64, S74 coronary heart disease, S8, S67–S68 albiglutide, S50, S53, S54, S56, S58 smoking and, S29, S89 correctional facilities, S106 albuminuria, S29, S72–S74, S90 care improvement strategies cultural differences, S8 alcohol, S26, S65 adherence, S8 cystic fibrosis, S18 alogliptin, S53–S55, S68 advocacy, S6, S105–S106 cystic fibrosis–related diabetes, S20 amlodipine, S63 Chronic Care Model, S7 amputation, S78 delivery systems, S7 dapagliflozin, S53, S54, S56, S58 amylin mimetics, S53, S56 demographics, S6 dementia, S9, S31–S32, S82 anemia, S14 institutional changes, S7–S8 depression, S10, S30 angiotensin receptor blockers, S61, S62, S68, intermediate outcomes, S8 Diabetes Control and Complications Trial S72–S74, S89, S97 objectives, S7–S8 (DCCT), S42, S44, S52, S87 antidepressants, S49 outcomes, S8 diabetes distress, S30 antihyperglycemic agents, S100–S101 patient-centered, S6 Diabetes Prevention Program (DPP), S36, S37 antihypertensive agents, S63, S97 processes of care, S8 Diabetes Prevention Program Outcomes Study antiplatelet agents, S4–S5, S66–S67, S75 recommendations, S6, S9, S10 (DPPOS), S36 antipsychotics, S49 team building, S7 Diabetes Prevention Recognition Program antiretroviral agents, S10 treatment intensification, S8 (DPRP), S37 Antithrombotic Trialists’ (ATT) metanalysis, S66 child care, school, S86–S87, S105 diabetes self-management education, support antivascular endothelial growth factor, S75, S76 children, adolescents (DSME, DSMS), S7, S8–S9, S24–S25, S36, Asian Americans, S8, S15, S17, S47 A1C levels in, S18, S41 S37, S86, S102 ASPIRE trial, S40 autoimmune diseases in, S87–S88 diabetic ketoacidosis (DKA), S13, S16–S17, S45, aspirin resistance, S67 celiac disease in, S88 S58, S90, S101 aspirin therapy, S4–S5, S66–S67, S75 diabetes management, S87 diabetic kidney disease, S27, S29, S72–S74 atherosclerotic cardiovascular disease. see DSME, DSMS, S7, S8–S9, S24–S25, S36, Diabetic Retinopathy Study, S76 cardiovascular disease S37, S86 diagnosis atorvastatin, S64 dyslipidemia management, S89 A1C (see A1C) autonomic neuropathy, S29, S76–S78 exercise for, S28 anemia, S14 a-glucosidase inhibitors, S37, S55 glycemic control, S87, S89 community screening, S17–S18 hypertension, S88–S89 comorbidities, S31–S32 bariatric surgery, S49–S51, S58 hypoglycemia in, S44, S87 confirmation of, S14 b-blockers, S74 nephropathy, S27, S29, S72–S74, S89–S90 fasting test, S13, S14 INDEX Belviq (lorcaserin), S50 neuropathy, S28–S29, S76–S78, S90 hemoglobinopathies, S14 benazepril, S63 pediatric to adult care transition, S91 monogenic syndromes, S19–S20 bile acid sequestrants, S55 psychosocial issues, S87 one-step strategy, S18–S20 bipolar disorder, S10 retinopathy, S28, S73–S76, S90 plasma glucose criteria, S13 blood glucose control. see glycemic control school, child care, S86–S87, S105 prediabetes, S14–S17, S36 blood pressure control, S60–S63, S81, S88–S89 screening, S87 red blood cell turnover, S14 S110 Index Diabetes Care Volume 39, Supplement 1, January 2016

referrals, S30 intercurrent illness, S45 treatment, S9, S44, S101–S102 2-hour plasma glucose, S13, S14 kidney disease treatment, S73–S74 type 1 diabetes, S44–S45 two-step strategy, S19, S20 neurocognitive function, S82 hypoglycemia unawareness, S44 type 1 diabetes (see type 1 neuropathy treatment, S77 diabetes) older adults, S82, S83 immune-mediated type 1 diabetes, S15 type 2 diabetes (see type 2 omega-3 fatty acids, S27 immunizations, S29–S30 diabetes) physical activity in, S28 IMPROVE-IT trial, S65 diastolic blood pressure, S62 pregnancy, S95 incident diabetes, statin use and, S66 diuretics, S61–S63, S74, S97 recommendations, S39, S43, S44 incretin-based therapies, S53 dopamine-2 agonists, S55 self-monitoring of blood glucose (SMBG), indapamide–perindopril, S62–S63 DPP-4 inhibitors, S53–S55, S58, S68, S101 S39–S40 infections, S79 driving, S105 targets, S43–S44 influenza, S29 dulaglutide, S50, S53, S54, S56, S58 GRADE study, S54 insulin, insulin secretagogues duloxetine, S77 grading system, S1–S2 basal, S40, S54, S57–S58 dyslipidemia, S65, S83, S89 bolus, S58 health care access, S8–S9 carbohydrate counting, S27 Early Treatment Diabetic Retinopathy health disparities, S8 characterization, S56 Study, S76 hearing impairment, S31 in children, adolescents, S90 eating patterns, S26 heart failure, S68 continuous subcutaneous infusion, S58 e-cigarettes, S29 hemoglobinopathies, S14 CVD targeting, S43 empagliflozin, S53, S54, S56, S58, S68 hepatitis B, S30 hospital care, S99, S100 EMPA-REG OUTCOME study, S56, S68 herbal supplements, S26 hypoglycemia unawareness, S44 employment, S105–S106 HITECH Act, S99–S100 inhaled, S58 end-of-life treatment, S82–S85 HIV patients, diabetes care in, S10 neurocognitive function, S82 energy balance, S26 homelessness, S9 older adults, S83 erectile dysfunction, S77–S78 hospital care oral agents, S40, S57–S58 ethnic differences, S8, S14, S17, S41 admission considerations, S100 physical activity, S28 euthyroid sick syndrome, S88 antihyperglycemic therapies, physiology in pregnancy, S95, S96 evaluation, S23, S24, S31 S100–S101 self-monitoring of blood glucose (SMBG), EXAMINE trial, S68 bedside glucose monitoring, S103 S39–S40 exenatide, S50, S53, S54, S56, S58 CGM, S39, S40, S101 type 1 diabetes, S52–S53 exercise, S27–S29, S37, S48 computerized physician order entry, insurance, S9 ezetimibe, S64, S65 S99–S100 islet cell transplantation, S53 critical care setting, S100 fasting test, S13, S14 diabetes self-management, S102 Japanese Americans, S17 fats, S26, S27. see also lipid management diabetic ketoacidosis (DKA), S13, S16–S17, fatty liver disease, S31 S45, S58, S90, S101 Kumamoto Study, S42 fibrate/statin therapy, S65 discharge plan, S102–S103 5-HT2C receptor agonists, S50 enteral/parenteral feeding, S101 fluvastatin, S64 glucocorticoids, S101 laser photocoagulation therapy, S75, S76 food insecurity, S9 glycemic control, S100, S101 LDL cholesterol, S64, S65, S68 foot care, S78–S79 hyperglycemia in, S100 lifestyle modification, S7, S36–S37, S47, S48, foundations of care, S23 hyperosmolar hyperglycemic state, S62–S64, S68 fractures, S31 S101 linagliptin, S53–S55 hypoglycemia, S99–S102 lipase inhibitors, S37, S50 – see also gabapentin, S77 insulin therapy, S99, S100 lipid management, S63 S66. fats fi gastrointestinal neuropathies, S77 medical nutrition therapy, lipid pro les, S65 gastroparesis, S77 S25–S27, S102 liraglutide, S50, S53, S54, S56, S58 genitourinary neuropathies, S77 perioperative care, S101 liraglutide (Saxenda), S50 fi gestational diabetes mellitus, S18–S20, S37, recommendations, S99 literacy de ciencies, S9 S94–S97 target glucose ranges, S99–S101 lixisenatide, S50, S53, S54, S56, S58 glibenclamide, S55 type 1 diabetes, S100 Look AHEAD, S47, S68 gliclazide, S55 HOT trial, S62 lorcaserin (Belviq), S50 glimepiride, S55 hydrochlorothiazide, S63 loss of protective sensation, S78 glipizide, S55 hyperglycemia, S9–S10, S42, S45, S96, lovastatin, S64 glomerular filtration rate estimation, S73 S99–S101 GLP-1 receptor agonists, S50, S53, S54, S56, S58, Hyperglycemia and Adverse Pregnancy macular edema, S75, S76 S83 Outcome (HAPO) study, S18 MAO inhibitors, S49 glucagon, S44 hypertension, S60–S63, S81, S88–S89 maturity-onset diabetes of the young (MODY), glucocorticoids, S101 hypertriglyceridemia, S65 S13, S19–S20 glucose, S44. see also glycemic control hypoglycemia medical evaluation, S31 glyburide, S55, S83, S96 in children, adolescents, S44, S87 medical nutrition therapy, S25–S27, S102. see glycemic control glycemic control, S27, S28, S40 also nutrition A1C (see A1C) hospital care, S99–S102 Medicare, S8, S25 carbohydrate counting, S27 maternal, S95 medications, S10, S17, S49, S103. see also under children, adolescents, S87, S89 nutrition in control of, S27 specific conditions continuous glucose monitoring (CGM), in older adults, S82, S84 Mediterranean diet, S10, S27, S37 S39, S40, S101 physical activity in control of, S28 meglitinides, S54, S55 hospital care, S100, S101 predictors of, S102 mental illness, S10 hyperglycemia, S9–S10, S42, S45, S96, prevention, S9, S27, S28, metformin S99–S101 S101–S102 cardiovascular disease, S67, S68 hypoglycemia (see hypoglycemia) symptoms, S10 children, adolescents, S90 care.diabetesjournals.org Index S111

effectiveness of, S36, S37 pancreatic transplantation, S53 scientific evidence grading, S1–S2 hospital care, S101 Patient-Centered Medical Home, S7 scientific statements, S1 older adults, S83 PCSK9 inhibitors, S65 SEARCH study, S89 in pregnancy, S96 percent of days covered (PDC), S8 self-monitoring of blood glucose (SMBG), therapy generally, S53–S55 perindopril–indapamide, S62–S63 S39–S40 metoclopramide, S77 periodontal disease, S31 sex differences, S8, S66–S67 miglitol, S55 peripheral arterial disease (PAD), S78 SGLT2 inhibitors, S53, S54, S56, S58, S83 mineralocorticoid receptor blockers, S74 peripheral neuropathy, S28–S29, S76–S78 simvastatin, S64 Modification of Diet in Renal Disease (MDRD) phentermine/topiramate combination, S50 sitagliptin, S53–S55, S68 study, S73 photocoagulation therapy, S75 smoking cessation, S29, S89 physical activity, S27–S29, S37, S48 socioeconomic differences, S8 naltrexone/bupropion (Contrave), S50 pioglitazone, S37, S54, S55 sodium, S26, S27 nateglinide, S54, S55 pitavastatin, S64 spironolactone, S74 neonatal diabetes, S19 plasma glucose criteria, S13 SPRINT trial, S61–S62 nephrologist, referrals to, S74 pneumococcal pneumonia, S29–S30 SSRIs, S49 nephropathy, S27, S29, S72–S74, S89–S90 pneumococcal polysaccharide vaccine 23 (PPSV23), Standards of Care, S1 neuropathy, S28–S29, S76–S78, S90 S29–S30 statins NHANES, S7, S14, S31 POC meters, S103 in CHD management, S68 niacin/statin therapy, S65–S66 position statements, S1 children, adolescents, S89 NICE-SUGAR study, S100 pramlintide, S53, S56 cognitive function and, S66 nonketotic hyperosmolar state, S45 pravastatin, S64 dementia and, S10 nucleoside reverse transcriptase inhibitors (NRTIs), S10 prediabetes, S14–S17, S36 in lipid management, S64–S66 numeracy deficiencies, S9 pregabalin, S77 type 1 diabetes, S64–S65 nutrition pregestational diabetes, S94–S96 type 2 diabetes, S63–S66 alcohol, S26, S65 pregnancy sulfonylureas, S54, S55, S58, S83, S96, S101 carbohydrates, S27, S37 A1C levels, S95 sympathomimetic amine anorectic/antiepileptic cognitive dysfunction and, S10 antihypertensive medications in, combination, S50 in diabetes prevention, S37 S63, S97 systolic blood pressure, S62 eating patterns, S26 blood pressure targets, S61 energy balance, S26 contraception, S97 tapentadol, S77 fats, S26, S27 gestational diabetes mellitus, TECOS trial, S68 – – herbal supplements, S26 S18 S20, S37, S94 S97 testosterone levels, S31 kidney disease treatment, S73 glucose monitoring, S95 thiazolidinediones, S37, S54, S55, S67, S83 macronutrient distribution, S26 glycemic control, S95 thyroid disease, S88 micronutrients, S26 hyperglycemia, S96 tobacco, S29, S89 older adults, S84 insulin physiology, S95, S96 TODAY study, S90 – protein, S26, S27 lactation, S96 S97 tramadol, S77 sodium, S26, S27 pharmacological therapy, S96, S97 Translating Research Into Action for Diabetes – postpartum care, S96 S97 (TRIAD) study, S8 preconception counseling, testing, S95 obesity treatment. see also specific therapies pregestational diabetes, S94–S96 assessment, S47 adherence, S8 recommendations, S94 bariatric surgery, S49–S51, S58 DSME, DSMS, S7, S8–S9, S24–S25 retinopathy, S75–S76 concomitant medications, S49 exercise, S27–S29, S37, S48 type 1 diabetes, S96–S97 diet, S48 (see also nutrition) foundations of care, S23 type 2 diabetes, S96–S97 lifestyle modification, S7, S36–S37, S47, glucose, S44 Professional Practice Committee, S3, S107–S108 S48, S62–S64, S68 hypoglycemia, S44 proliferative diabetic retinopathy, S75, S76 pharmacotherapy, S48–S50 immunizations, S29–S30 protease inhibitors, S10 physical activity, S27–S29, S37, S48 initial care basis, S23–S24 protein, S26, S27 recommendations, S48 intensification, S8 psychosocial issues, S30, S87 treatment, S47, S48 lifestyle modification, S7, S36–S37, S47, P2Y12 receptor antagonists, S67 weight management, S25–S27, S68 S48, S62–S64, S68 obstructive sleep apnea, S31 medical nutrition therapy, S25–S27, S102 olanzapine, S49 red blood cell turnover test, S14 ongoing care, S24 older adults referrals, S24, S30, S74, S75 patient engagement, S23 end-of-life treatment, S82–S85 reimbursement, DSME/DSMS, S25 pharmacological, S36, S37 geriatric syndromes screening, S81 renal function assessment, S72–S73 psychosocial issues, S30 hypertension, S81 repaglinide, S54, S55 referrals, S24 hypoglycemia, S82, S84 resistance training, S27 smoking cessation, S29, S89 long-term care facilities, S81, S84 retinal photography, S75 tailoring, S8–S9 neurocognitive function, S82 retinopathy, S28, S73–S76, S90 technology in, S37 nutrition, S84 revisions summary, S4–S5 type 1 diabetes, S52–S53 overview, S81–S82 Reye syndrome, S67 type 2 diabetes, S53–S58 palliative care, S60–S63, S81 risperidone, S49 weight management, S25–S27, S68 pharmacological therapy, S83–S84 rosiglitazone, S37, S54, S55 tricyclic antidepressants, S49, S77 recommendations, S81 rosuvastatin, S64 2-hour plasma glucose, S13, S14 treatment, S82–S83 type 1 diabetes omega-3 fatty acids, S27 SAVOR-TIMI 53 trial, S68 A1C microvascular complications, S42 ophthalmologist, referrals to, S75 saxagliptin, S53–S55, S68 carbohydrate counting, S27 opioid antagonist/aminoketone antidepressant Saxenda (liraglutide), S50 in children, adolescents, S86–S90 combination, S50 schizoaffective disorder, S10 classification, S13 orlistat, S37, S50 schizophrenia, S10 CVD outcomes and, S42 orthostatic hypotension, S77 school, child care, S86–S87, S105 demographics, S6 S112 Index Diabetes Care Volume 39, Supplement 1, January 2016

diagnosis, S15–S16 BMI, ethnicity factors, S17 pharmacological therapy, S53–S58 differential diagnosis, S18 carbohydrate counting, S27 pregnancy, S96–S97 epidemiology, S8 children, adolescents, S18, S19 prevention, delay, S36–S37 glycemic control, S39 in children, adolescents, S90–S91 resistance training, S27 hospital care, S100 classification, S13 retinopathy, S75 hypoglycemia, S9, S44–S45 combination therapy, S53–S57 risk factors, S17 idiopathic, S15–S16 CVD outcomes and, S42–S43 statin therapy, S63–S66 immune-mediated, S15 demographics, S6, S8 pharmacological therapy, S52–S53 diagnosis, S16–S19 UK Prospective Diabetes Study (UKPDS), S42, – physical activity, S27 S29 differential diagnosis, S18, S19 S67, S74 pregnancy, S96–S97 exercise, S27–S29 retinopathy, S75 glycemic control, S40 risk factors, S16 hyperglycemia in, S9–S10 venlafaxine, S77 statin therapy, S64–S65 hypoglycemia, S9 Veterans Affairs Diabetes Trial (VADT), S42–S43 type 2 diabetes hypoglycemia in, S10 vildagliptin, S53–S55 A1C microvascular complications, S42 mental illness in, S10 bariatric surgery, S49–S51, S58 obesity in, S48 weight management, S25–S27, S68